{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:58:02Z","timestamp":1786121882490,"version":"build-2736575974"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2026,7,27]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Glioblastoma (GBM), an aggressive and highly recurrent brain tumor, remains a\nsignificant challenge despite advancements in treatment. With a median survival of only 15 months and recurrence often occurring within a year despite aggressive initial therapy, there is an urgent need for more effective\ntherapeutic strategies. The interplay of intrinsic and extrinsic factors, such as genetic mutations and alterations\nin the tumor microenvironment, drives recurrence, highlighting the importance of targeted approaches. Emerging therapies, particularly dendritic cell (DC)-based immunotherapies, show promise in enhancing anti-tumor\nimmune responses. This study aimed to compare the effectiveness of DC-based immunotherapy in improving\nsurvival outcomes for patients with newly diagnosed or recurrent GBM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a comprehensive search across four electronic databases (Cochrane Central Register of\nControlled Trials, PubMed, Scopus, and Web of Science) up to March 2024 to identify pertinent studies evaluating the efficacy of DC vaccines in the treatment of both newly diagnosed and recurrent GBM. The quality of\nevidence from trials was assessed using the Cochrane risk-of-bias version 1 (RoB1) tool. Data from the included\nstudies were extracted into a standardized online sheet and analyzed using Review Manager (RevMan) 5.4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Our search identified three records with a total of 355 patients. The results of the meta-analysis showed\nthat DC-based immunotherapy had a greater impact on recurrent GBM than on newly diagnosed GBM. However, overall survival favored newly diagnosed cases, demonstrating a more protective effect (HR = 0.62, 95%\nconfidence intervals (CI) (0.46,0.84), p = 0.002) with no significant heterogeneity (p = 0.97, I2 = 0%). A similar\ntrend was observed for progression-free survival, favoring newly diagnosed cases over recurrent ones\n(HR = 0.56, 95% CI (0.31,1.00), p = 0.05), with no significant heterogeneity (p = 0.48, I2 = 0%). Moreover,\ncomparable results were observed for survival at both 12 and 24 months<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Dendritic cell-based immunotherapy can enhance survival outcomes in GBM patients. The results\nshowed DC-based immunotherapy to be more effective in newly diagnosed GBM than in recurrent cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0118715206406017251124090916","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T07:56:26Z","timestamp":1785138986000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dendritic Cell Vaccines for Glioblastoma: A Systematic Review and Meta-Analysis\nComparing New-Onset and Recurrent Cases"],"prefix":"10.2174","volume":"26","author":[{"given":"Abdulsalam","family":"Mohammed Aleid","sequence":"first","affiliation":[{"name":"Department of Surgery, Medical College, King Faisal University, Ahsa, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Abdullah Houlbah","sequence":"additional","affiliation":[{"name":"College of Medicine, Jazan University,Jazan, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Yahya Abutaleb","sequence":"additional","affiliation":[{"name":"College of Medicine, King Khalid University, Abha, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Mohammed Hakami","sequence":"additional","affiliation":[{"name":"King Fahad Central Hospital, JazanHealth Cluster, Jazan, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Ali M. Alshahrani","sequence":"additional","affiliation":[{"name":"College of Medicine, King Khalid University, Abha, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Khalid Aldawsari","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaa","family":"Ahmed Salem Algethmi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, KingAbdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-9901","authenticated-orcid":true,"given":"Alaa","family":"Abdulrahman Ismail","sequence":"additional","affiliation":[{"name":"Department of Microbiology, College of Medicine, Taif University, Taif, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Fadhel Almalki","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medical College, King Faisal University, Ahsa, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715206406017251124090916","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/256666\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715206406017251124090916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T07:36:55Z","timestamp":1786088215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/256666\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0118715206406017251124090916","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-04-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}